Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator application
The submission to the Therapeutic Goods Administration was prepared by the Intellectual Property Committee of the Business Law Section.
The Committee makes the following comments in relation to the consultation regarding ‘Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator application’ (March 2020).
You can read the full submission below.
Last Updated on 05/06/2020
Share
Related Documents
Tags
Most recent items in Business Law Section
Business Law Section
Strategic Examination of Research and Development (R&D)
Business Law Section
Addressing corporate misuse of the Fair Entitlements Guarantee – Discussion Paper
Business Law Section
Consultation Statement 16 Reportable Situations – Additional Relief (CS 16)
Trending Items in Business Law Section
Business Law Section
Forsyth/Pose Scholarship
Business Law Section
Santow Scholarship
Business Law Section